Grape King BioTPE:1707 -0.11%78 Operating Margin % is 24.76% as of Dec. 2025, which is 2% above its 10-year median of 24.17. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$144.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Grape King Bio ranks better than 83.05% on this metric.
Grape King Bio Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -3.2%.
The historical rank and industry rank for Grape King Bio's Operating Margin % or its related term are showing as below:
TPE:1707'
s Operating Margin % Range Over the Past 10 Years
Min: 20.88 Med: 24.17 Max: 25.59
Current: 20.88
TPE:1707's Operating Margin % is ranked better than 83.05% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.58
vs TPE:1707: 20.88
Grape King Bio's 5-Year Average Operating Margin % Growth Rate was -3.20% per year.
Grape King Bio's Operating Income for the
three
months ended in Dec. 2025 was NT$743 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2,141 Mil.
Grape King Bio (TPE:1707) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Grape King Bio Operating Margin % Related Terms
Grape King Bio Operating Margin % Historical Data
* Premium members only.
The historical data trend for Grape King Bio's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1707 vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Grape King Bio's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Grape King Bio's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) has a Operating Margin % of 24.76% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Grape King Bio and its competitors. This is near median its historical median of 24.17. Over the past decade, Grape King Bio's Operating Margin % has ranged from 20.88 to 25.59. According to the industry distribution chart, Grape King Bio ranks #162 out of 956 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is Grape King Bio's Operating Margin % too high?
Grape King Bio's current Operating Margin % of 24.76% is near median its 10-year median of 24.17. Over the past 10 years, this metric has ranged from a low of 20.88 to a high of 25.59. The Drug Manufacturers industry median Operating Margin % is 7.58. Grape King Bio's value of 24.76% is 226.6% above this industry median. Based on the distribution chart, Grape King Bio ranks #162 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #162 out of 956 companies for Operating Margin %. This places Grape King Bio in the top 17% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.58. Grape King Bio's value of 24.76% is 226.6% above this benchmark. Historically, Grape King Bio's own Operating Margin % has ranged from 20.88 to 25.59 over the past decade. While the company's 10-year median is 24.17 vs. the industry median of 7.58, Grape King Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current Operating Margin % of 24.76% is 226.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current Operating Margin % is 24.76%, which is near median its own 10-year median of 24.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.03, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current Operating Margin % is 24.76%, which is near median its 10-year median of 24.17 and 226.6% above the Drug Manufacturers industry median of 7.58. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Operating Margin % is 24.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.03.
GuruFocus considers Grape King Bio to be Possible Value Trap.
Key valuation signals for TPE:1707:
Operating Margin %: 24.76% (near median its 10-year median of 24.17)
GF Value™: NT$144.03 vs. price of NT$91.00 (36.8% below fair value)
Industry Position: 226.6% above the Drug Manufacturers median (#162 of 956)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score
Get the complete analysis for TPE:1707
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
